Provided by Tiger Fintech (Singapore) Pte. Ltd.

AlphaTON Capital Corp.

10.91
+5.3395.52%
Post-market: 8.80-2.1100-19.34%19:59 EDT
Volume:29.64M
Turnover:406.57M
Market Cap:24.86M
PE:-1.91
High:13.80
Open:13.25
Low:9.77
Close:5.58
52wk High:15.82
52wk Low:2.95
Shares:2.28M
Float Shares:1.43M
Volume Ratio:11.31
T/O Rate:2065.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.7202
EPS(LYR):-5.7202
ROE:-541.81%
ROA:-92.69%
PB:-202.11
PE(LYR):-1.91

Loading ...

Company Profile

Company Name:
AlphaTON Capital Corp.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
4
Office Location:
Clarence Thomas Building,P.O. Box 4649,Road Town,Tortola,Tortola,British Virgin Islands
Zip Code:
VG1110
Fax:
- -
Introduction:
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.

Directors

Name
Position
Alexander Pickett
Chief Executive Officer and Director
Justin Stebbing
Director and Chairman of the Board
Gregory H. Bailey
Director
James Mellon
Director
Jean Christophe Renondin
Director
Steven Mintz
Director

Shareholders

Name
Position
Alexander Pickett
Chief Executive Officer and Director
Andrea E. Park
Chief Financial Officer
Robert Kramer
Chief Scientific Officer